[21] AVGO, BIDU, MRNA
The information and materials provided here, whether or not provided on TBI’s Substack (TBI), on third party websites, in marketing materials, newsletters or any form of publication are provided for general information and circulation only.
None of the information contained here constitutes an offer (or solicitation of an offer) to buy or sell any currency, product or financial instrument, to make any investment, or to participate in any particular trading strategy.
TBI does not take into account of your personal investment objectives, specific investment goals, specific needs or financial situation and makes no representation and assumes no liability to the accuracy or completeness of the information provided here. The information and publications are not intended to be and do not constitute financial advice, investment advice, trading advice or any other advice or recommendation of any sort offered or endorsed by TBI. TBI also does not warrant that such information and publications are accurate, up to date or applicable to the circumstances of any particular case. Any expression of opinion (which may be subject to change without notice) is personal to TBI and TBI makes no guarantee of any sort regarding accuracy or completeness of any information or analysis supplied. TBI is not responsible for any loss arising from any investment based on any perceived recommendation, forecast or any other information contained here. The contents of these publications should not be construed as an express or implied promise, guarantee or implication by TBI that you will profit or that losses in connection therewith can or will be limited, from reliance on any information set out here.
Third of the week! Let’s review a few more names:
Broadcom Inc. (NASDAQ: AVGO)
AVGO is currently trading in the green ascending channel. Towards the end of last year, it rejected off the 1.618 Fib extension at 381.89 alongside channel resistance.
Since then, AVGO has been in a correction and is currently sitting just above the 321.42 quarterly support.
If AVGO breaks and closes below this quarterly level, it's likely to see downside continuation into the channel support. Note that AVGO is yet to retest its prior swing high at 251.88.
Otherwise, AVGO could come back into the 353-355 weekly resistance next.
Baidu, Inc. (NASDAQ: BIDU)
BIDU broke out of its dark blue resistance trendline in the second half of 2025. Since then, it has been trying to push above the lower Fib levels.
It rejected off the 159.57 Fib level and came back into the short-term blue support trendline while retesting the 134 monthly level.
If BIDU breaks down below the 131.02 Fib level sitting just below the monthly level, and below the support trendline, then it could retrace into 116.
Otherwise, BIDU could range back into the 159.57 Fib level, with a breakout above this level likely resulting in continuation into the 172-174 half-yearly imbalance.
Moderna, Inc. (NASDAQ: MRNA)
MRNA has been in a correction for the past 5 years. It recently retested its 2018 IPO candle high at 22.75 and has since rallied strongly off that level.
It recently rejected off the 50.94 Fib level and is now pulling back into the 35.80 quarterly level.
MRNA is still trading below its main red resistance trendline. If MRNA breaks below 35.80, it can see a larger pullback into the 29.79 yearly level.
Otherwise, if 35.80 remains intact, MRNA could range back into the 50.94 Fib level, with a breakout above that level seeing continuation into the red resistance trendline.
@TigerWire @TigerStars @TigerEvents @CaptainTiger @MillionaireTiger
$Broadcom(AVGO)$ $Baidu(BIDU)$ $Moderna, Inc.(MRNA)$ $Amazon.com(AMZN)$ $Meta Platforms, Inc.(META)$
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
